Bio­gen clos­es out its oph­thal­mol­o­gy R&D work, dump­ing off a C3 ther­a­py

A few weeks af­ter South San Fran­cis­co-based Cat­a­lyst Bio­sciences brought in some ad­vis­ers to help suss out their “strate­gic op­por­tu­ni­ties,” the crew at the strug­gling …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER